Clinical trials: Complicated Intra Abdominal Infections
Infections, Intestinal
GSK2251052 in the Treatment of Complicated Intra-abdominal Infections
This study is being conducted to evaluate the safety, efficacy and pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal infections.
- Trial name
- NCT01381562
- Testing
- Drug: GSK2251052, Meropenem
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Gram-negative Bacterial Infections, Bloodstream Infections (BSI)
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
The primary objectives of this study are: To assess the safety and tolerability of cefiderocol after single-dose administration in hospitalized paediatric participants 3 months to < 18 years of age with suspected or confirmed…
- Conditions
- Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI), Hospital Acquired Pneumonia (HAP)
- Trial name
- NCT04335539
- Testing
- Cefiderocol, Standard of Care
- Where
- 23 sites in Belgium, Estonia and 7 more
- Volunteers
- 53 people
- Sponsor
- Shionogi
Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections
Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment
The primary objective of this study is to identify any changes on the safety profile of adverse events and serious adverse events.
- Conditions
- Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections, Community-Acquired Bacterial Pneumonia
- Trial name
- NCT01072539
- Testing
- tigecycline
- Where
- 36 sites in South Korea
- Volunteers
- 3,172 people
- Sponsor
- Pfizer
Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL) for the treatment of serious infections due to Gram…
- Conditions
- Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
- Trial name
- REVISIT (NCT03329092)
- Testing
- ATM-AVI, MTZ, MER
- Where
- 157 sites in United States, Argentina and 19 more
- Volunteers
- 422 people
- Sponsor
- Pfizer
Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and
Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP
Reporting patterns and results of initial antibiotic treatment in patients with complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI) and nosocomial pneumonia (NP) including…
- Conditions
- Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and, Nosocomial Pneumonia (NP)
- Trial name
- RECOMMEND (NCT02364284)
- Where
- 27 sites in Brazil, France and 4 more
- Volunteers
- 1,322 people
- Sponsor
- Pfizer
Intraabdominal Infections
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
The primary focus of the study is the evaluation of the safety of treatment with moxifloxacin in a pediatric population 3 months to <18 years old.
- Trial name
- MOXIPEDIA (NCT01069900)
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate
- Where
- 39 sites in United States, Argentina and 14 more
- Volunteers
- 458 people
- Sponsor
- Bayer
Gram-Positive Bacterial Infections, Cross Infection
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
- Trial name
- NCT00081744
- Testing
- Tigecycline
- Volunteers
- 850 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
The purpose of this study is to learn about the safety and effectiveness of Zavicefta once released into the markets in Korea. This study is to learn about Zavicefta in patients with difficult types of infections in the abdomen…
- Conditions
- Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection, Hospital-acquired Pneumonia
- Trial name
- NCT05733104
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Pfizer
Complicated Intra-abdominal Infection
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
A Phase 2, multicenter, prospective, randomized, double-blind study of CXA-101/ tazobactam (1000/500 mg q8h) and metronidazole (500 mg q8h) IV infusion vs.
- Trial name
- NCT01147640
- Testing
- CXA-101/ tazobactam and metronidazole
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 122 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Complicated Intra-abdominal Infections
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.
- Trial name
- NCT00752219
- Testing
- ceftazidime/NXL104 + metronidazole, meropenem
- Where
- 45 sites in United States, Bulgaria and 6 more
- Volunteers
- 204 people
- Sponsor
- Pfizer
Complicated Urinary Tract Infection, Acute Pyelonephritis
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the…
- Conditions
- Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- Integral-2 (NCT05905055)
- Testing
- co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT
- Where
- 54 sites in China, Croatia and 12 more
- Volunteers
- 126 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT01602874
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Pfizer
Complicated Intra-abdominal Infections
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
This study aims to evaluate the efficacy of ceftolozane/tazobactam (MK-7625A) plus metronidazole versus meropenem in adults diagnosed with complicated intra-abdominal infection (cIAI).
- Trial name
- 7625ACNPhase3 (NCT03830333)
- Testing
- Ceftolozane/Tazobactam, Metronidazole, Meropenem
- Where
- 25 sites in China
- Volunteers
- 268 people
- Sponsor
- Merck Sharp & Dohme LLC
Appendicitis, Cholecystitis
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
This is a phase 3b/4 randomized, open-label, comparative, multicenter study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI (Complicated Intra-Abdominal…
- Conditions
- Appendicitis, Cholecystitis, Cross Infection, Diverticulitis
- Trial name
- NCT00195351
- Testing
- tigecycline, ceftriaxone sodium + metronidazole
- Where
- 66 sites in United States, Argentina and 4 more
- Volunteers
- 467 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Abdominal Abscess
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI
In light of tigecycline's activity against these resistant bacteria, tigecycline may represent a viable new therapy for complicated intra-abdominal infections.
- Trial name
- NCT00488306
- Testing
- tigecycline
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Complicated Intra-abdominal Infection
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared with ertapenem in the treatment of adult…
- Trial name
- NCT01265784
- Testing
- TP-434, Ertapenem
- Where
- 38 sites in United States, Bulgaria and 4 more
- Volunteers
- 143 people
- Sponsor
- Tetraphase Pharmaceuticals, Inc
Intra-abdominal Infections
Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
The purpose of this study is to evaluate the efficacy, safety and tolerability of adding 125 mg or 250 mg doses of relebactam (MK-7655) to imipenem/cilastatin in adults 18 years or older with Complicated Intra-Abdominal Infection…
- Trial name
- NCT01506271
- Testing
- Relebactam 250 mg, Relebactam 125 mg, Imipenem/cilastatin
- Volunteers
- 351 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Intra-Abdominal Infection
Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial…
- Trial name
- NCT00929643
- Testing
- no intervention
- Where
- 13 sites in Greece
- Volunteers
- 203 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
To Evaluate the Effects of Ceftazidime-Avibactam and Best Available Therapy in patients with complicated urinary tract infections and complicated intra-abdominal infections.
- Trial name
- NCT01644643
- Testing
- Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
- Where
- 43 sites in United States, Argentina and 16 more
- Volunteers
- 345 people
- Sponsor
- Pfizer
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (IMI/REL, MK-7655A) in Japanese participants with complicated intra-abdominal infection (cIAI) or complicated urinary tract infection (cUTI).
- Trial name
- NCT03293485
- Testing
- Imipenem+Cilastatin/Relebactam
- Where
- 29 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Merck Sharp & Dohme LLC